SMS PHARMACEUTICALS LTD. Q4 FY26 Results

Summary

SMS Pharmaceuticals Limited concluded FY26 with a revenue from operations of ₹88,687.10 lakhs, representing a 13.30% increase year-on-year. The net profit after tax for the full financial year grew by 5.64% to ₹936.52 lakhs, with earnings per share reaching ₹2.43. For the fourth quarter of FY26, the company's revenue from operations was ₹23,794.75 lakhs, indicating a 4.13% decrease from the prior year's fourth quarter, while net profit after tax for Q4 saw an 18.71% rise to ₹9.58 lakhs. Additionally, the Board recommended a final dividend of ₹0.40 Paise per equity share for FY26.

Key Highlights

1. 1

   SMS Pharmaceuticals Limited reported a 13.30% year-on-year increase in revenue from operations, reaching ₹88,687.10 lakhs for the financial year ended March 31, 2026.

2. 2

   The net profit after tax for FY26 grew by 5.64% to ₹936.52 lakhs, up from ₹886.52 lakhs in the previous financial year.

3. 3

   Earnings per equity share (Basic / Diluted) for FY26 improved to ₹2.43, compared to ₹2.25 recorded in FY25.

4. 4

   For the fourth quarter of FY26, revenue from operations was ₹23,794.75 lakhs, marking a 4.13% decline year-on-year.

5. 5

   Net profit after tax for Q4 FY26 saw an increase of 18.71% to ₹9.58 lakhs, compared to ₹8.07 lakhs in the corresponding quarter of FY25.

6. 6

   The Board of Directors recommended a final dividend of ₹0.40 Paise (40%) per equity share of face value ₹1/- for the financial year 2025-26, pending member approval.

7. 7

   The company approved the shifting of its Registered Office within the local limits of Hyderabad, effective May 25, 2026.